StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > 20 min rapid testing. How will this effect us😬

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Nov 29, 2020 5:03pm

274 Views

Post# 31997481

RE:RE:RE:RE:20 min rapid testing. How will this effect us😬

LithLover wrote: Yup $2 million cash end of Sept. $5-12 million with offering. A couple more quarters of Covid say $4-6 million ($1-2 profit). Builds a nice war chest for Aristotle.

Could be looking at $10 million or more at the end of Covid. For a company with a market cap of $37 million to have $10 million in cash does that make sense?

Keep making hay while the sun is shining Trippster.

Nailbiter1 wrote:

Positivelive1 wrote: Not at all- Covid is a side issue for SZLS- the real issue is Aristotle!

Yup. Ride the tiger while it lasts.When covid is a non issue, cancer tests will revive.

And $4-6 million is probably conservative, even with the advent of a vaccine lurking somewhere in the near future, it will still have lots of hiccups and gradual implementation. The big key now is to get Aristotle out there as quickly as possible so we remain leading edge without serious competition. The largest and most significant challenge will be the announcement of a credible partner (hospital-medical service network) to implement the virtues of Aristotle - after that word of mouth and success of practice would take over - the adaptation of it on a widespread basis is what we all wish to see as only acceptance of it will validate its ultimate worth.

)